Prognostic significance of dysadherin expression in advanced colorectal carcinoma

S. Aoki, T. Shimamura, T. Shibata, Y. Nakanishi, Y. Moriya, Y. Sato, M. Kitajima, Michiie Sakamoto, S. Hirohashi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.

Original languageEnglish
Pages (from-to)726-732
Number of pages7
JournalBritish Journal of Cancer
Volume88
Issue number5
DOIs
Publication statusPublished - 2003 Mar 10

Fingerprint

Colorectal Neoplasms
Cadherins
Neoplasms
Survival Rate
Recurrence
Cell Adhesion
Glycoproteins
Down-Regulation
Epithelium
Neoplasm Metastasis
Lung
Survival

Keywords

  • Colorectal carcinoma
  • Dysadherin
  • Immunohistochemistry
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aoki, S., Shimamura, T., Shibata, T., Nakanishi, Y., Moriya, Y., Sato, Y., ... Hirohashi, S. (2003). Prognostic significance of dysadherin expression in advanced colorectal carcinoma. British Journal of Cancer, 88(5), 726-732. https://doi.org/10.1038/sj.bjc.6600778

Prognostic significance of dysadherin expression in advanced colorectal carcinoma. / Aoki, S.; Shimamura, T.; Shibata, T.; Nakanishi, Y.; Moriya, Y.; Sato, Y.; Kitajima, M.; Sakamoto, Michiie; Hirohashi, S.

In: British Journal of Cancer, Vol. 88, No. 5, 10.03.2003, p. 726-732.

Research output: Contribution to journalArticle

Aoki, S, Shimamura, T, Shibata, T, Nakanishi, Y, Moriya, Y, Sato, Y, Kitajima, M, Sakamoto, M & Hirohashi, S 2003, 'Prognostic significance of dysadherin expression in advanced colorectal carcinoma', British Journal of Cancer, vol. 88, no. 5, pp. 726-732. https://doi.org/10.1038/sj.bjc.6600778
Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y et al. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. British Journal of Cancer. 2003 Mar 10;88(5):726-732. https://doi.org/10.1038/sj.bjc.6600778
Aoki, S. ; Shimamura, T. ; Shibata, T. ; Nakanishi, Y. ; Moriya, Y. ; Sato, Y. ; Kitajima, M. ; Sakamoto, Michiie ; Hirohashi, S. / Prognostic significance of dysadherin expression in advanced colorectal carcinoma. In: British Journal of Cancer. 2003 ; Vol. 88, No. 5. pp. 726-732.
@article{31d09b0184854d0eac7987d5a95e51bb,
title = "Prognostic significance of dysadherin expression in advanced colorectal carcinoma",
abstract = "A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50{\%} of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.",
keywords = "Colorectal carcinoma, Dysadherin, Immunohistochemistry, Prognosis",
author = "S. Aoki and T. Shimamura and T. Shibata and Y. Nakanishi and Y. Moriya and Y. Sato and M. Kitajima and Michiie Sakamoto and S. Hirohashi",
year = "2003",
month = "3",
day = "10",
doi = "10.1038/sj.bjc.6600778",
language = "English",
volume = "88",
pages = "726--732",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Prognostic significance of dysadherin expression in advanced colorectal carcinoma

AU - Aoki, S.

AU - Shimamura, T.

AU - Shibata, T.

AU - Nakanishi, Y.

AU - Moriya, Y.

AU - Sato, Y.

AU - Kitajima, M.

AU - Sakamoto, Michiie

AU - Hirohashi, S.

PY - 2003/3/10

Y1 - 2003/3/10

N2 - A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.

AB - A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.

KW - Colorectal carcinoma

KW - Dysadherin

KW - Immunohistochemistry

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0037430034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037430034&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600778

DO - 10.1038/sj.bjc.6600778

M3 - Article

C2 - 12618882

AN - SCOPUS:0037430034

VL - 88

SP - 726

EP - 732

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -